RIGL Q4 2018 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M

Gross Profit

$38M99.5% margin

Operating Income

$3M6.7% margin

Net Income

$3M8.5% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+678.2%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$139M

Total Liabilities

$29M

Stockholders' Equity

$110M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$0	—
Gross Profit	$38M	-$12M	+425.8%
Operating Income	$3M	-$26M	+109.7%
Net Income	$3M	-$26M	+112.5%